CONSENSO Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19

  • Juan Alejandro Ospina Idárraga Universidad El Bosque Instituto Nacional de Cancerología de Colombia E.S.E. Los COBOS medical center Bogotá Colombia Asociación Colombia de Hematología y Oncologia
  • Humberto Martinez-Cordero Jefe del servicio de Hematología y Trasplante de Medula Ósea Instituto Nacional de Cancerología de Colombia E.S.E. Asociación Colombia de Hematología y Oncologia https://orcid.org/0000-0002-7920-5951
  • Henry Idrobo Quintero Universidad del ValleUniversidad del Valle Universidad Libre Asociación Colombia de Hematología y Oncologia Hospital Universitario del Valle Grupo Ospedale, Grupo Christus
  • Conrad Ortiz Alfaro Facultad de Medicina, Universidad Peruana de Ciencias Aplicadas
  • Lina María Martínez Correa Sociedad de hematología, oncología y trasplante SHOT SAS
  • Juan Esteban Garcia Centro de Investigaciones Clínicas, Fundación Valle de Lili
  • Luis Malpica División de Hematología y Oncología Universidad de Carolina del Norte
  • Jorge Castillo División de Oncología Médica Danna-Farber Cancer Institute, Harvard Medical School Boston, MA USA
  • Maria Alejandra Torres Clínica Sanata Sofia, Instituto de Oncologia y Hematología, Universidad Central de Venezuela
  • Luis Villela Universidad del Valle de México. Campus Hermosillo, Sonora. Centro Médico Dr. Ignacio Chávez, ISSSTESON, Hermosillo, Sonora
  • Myrna Candelaria Instituto Nacional de Cancerología México. Universidad Nacional Autónoma de México
  • Alana Von Glasenapp Hospital Central Instituto de Previsión Social Universidad Católica Nuestra Señora de la Asunción Universidad del Norte Instituto Nacional de Ablación y Trasplante
  • Brady Beltran Hospital Nacional Edgardo Rebagliati Martins Centro de Investigación de Medicina de Precisión-Universidad de San Martín Porres
  • Sally Paredes Hospital Nacional Edgardo Rebagliati Martins Centro de Investigación de Medicina de Precisión-Universidad de San Martín Porres
  • Denisse Castro Hospital Nacional Edgardo Rebagliati Martins Centro de Investigación de Medicina de Precisión-Universidad de San Martín Porres
  • Virginia Prates Hospital Italiano La Plata
  • Marcos Di Stefano Hospital Solo Espinoza Ayala SOLCA - QUITO Universidad San Francisco de Quito. Hospital de los Valles
  • Eloísa Riva Hospital de Clínicas, Facultad de medicina Jefe de hematología – Asociación Española
  • Virginia Abello Polo Fundación Universitaria de Ciencias de la Salud Clínica del Country Asociación Colombia de Hematología y Oncologia Bogotá, Colombia
  • Juan Antonio Choque Supervisor de Hospitales Regional Caja Nacional de Salud Hospital Materno Infantil CNS Hospital Arco Iris
  • Camila Peña Hospital del Salvador
  • Christine Rojas Hospital Gustavo Fricke
  • Fabiola Valvert Gamboa Liga Nacional contra el Cáncer Instituto de Cancerología Hospital Bernardo del Valle S
  • Lorena Fiad Hospital Italiano La Plata
Palabras clave: COVID-19, Linfoma, tratamiento farmacológico

Resumen

En diciembre de 2019 se detectó por primera vez en China la existencia del SARS-CoV2, causante de la enfermedad COVID-19. El virus rápidamente se propagó por Europa y Asia, tardándose un par de meses antes de llegar a América Latina. Se ha demostrado que los pacientes que desarrollan una enfermedad severa y que tienen mayor riesgo de mortalidad por COVID-19 son aquellos con edades avanzadas y que presentan por lo menos una enfermedad crónica, incluyendo el cáncer. Debido a lo anterior, surgen muchas dudas en el grupo de profesionales encargados de brindar tratamiento a pacientes con cáncer durante la pandemia, pues se debe equilibrar el riesgo-beneficio de proveer tratamiento a pacientes que se encuentran de base con un riesgo incrementado para tener manifestaciones severas por COVID-19. En este consenso planteamos recomendaciones para los profesionales en hematología que brindan tratamiento a pacientes que padecen de algún tipo de linfoma, con el fin de aclarar el panorama clínico durante la pandemia.

Referencias

AABB. Statement on Coronavirus and Blood Donation. 2020; Available at: http://www.aabb.org/advocacy/regulatorygovernment/Pages/Statement-on-Coronavirus-and-Blood-Donation.aspx. Accessed Apr 07, 2020.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017 Nov;25(11):3295-3304.

Achard V., Tsoutsou P., Zilli T. Radiotherapy in the time of the Coronavirus pandemic: when less is better. Int J Radiat Oncol Biol Phys. 2020 Mar 18. pii: S0360-3016(20)30931-7. doi: 10.1016/j.ijrobp.2020.03.008. [Epub ahead of print]

Acute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica. 2005;90:ECR10

Adhikari, S. P. et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect. Dis. poverty 9, 29 (2020).

Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane database Syst Rev. 2020 Jan;1:CD012643.

Al-Shamsi H., Alhazzani W., Alhuraij A., Coomes E., Chemal R., et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. The Oncologist 2020;25:1–10

American Medical Association. AMA quick guide to telemedicine in practice. 2020; Available at: https://www.ama-assn.org/practice-management/digital/ama-quick-guide-telemedicine-practice. Accessed Apr 3, 2020.

American Society of Hematology. COVID-19 and Aggressive Lymphoma: Frequently Asked Questions. 2020; Available at: https://www.hematology.org/COVID-19/COVID-19-and-aggressive-lymphoma. Accessed Apr 5, 2020.

American Society of Hematology. COVID-19 and Aggressive Lymphoma: Frequently Asked Questions. 2020; Available at: https://www.hematology.org/COVID-19/COVID-19-and-aggressive-lymphoma. Accessed Apr 5, 2020

American Society of Hematology. COVID-19 Resources. 2020; Available at: https://www.hematology.org/covid-19. Accessed Apr 4, 2020.

American Society of Hematology. COVID-19 Resources. 2020; Available at: https://www.hematology.org/COVID-19/COVID-19-and-indolent-lymphomas.. Accessed Apr 4, 2020.

American Society of Hematology. Recomendaciones de la Sociedad Argentina de Hematología (SAH) . Available at: https://www.hematology.org/COVID-19/COVID-19-and-aggressive-lymphoma. Accessed Mar 30, 2020

Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 89, 44–48 (2020).

Arvedson T., O’Kelly J., Yang B., Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor. BioDrugs. 2015; 29(3): 185–198.

ASCO. COVID-19 Patient Care Information. 2020; Available at: https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19. Accessed Apr 04, 2020.

ASTRO guidance, COVID-19 Recommendations to radiation Oncology Practices. Available at: https://www.astro.org/Daily-Practice/COVID-19-Recommendations-and-Information. Accessed Apr 03, 2020.

ATA. 2019 State of the States Report: Coverage and Reimbursement. Available at: https://www.americantelemed.org/initiatives/2019-state-of-the-states-report-coverage-and-reimbursement/. Accessed Apr 4, 2020.

Ayers E., Shaoying L., Medeiros L., Bond D., Maddocks K., et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 Jan 15;126(2):293-303.

Barquín A., Molina J., Garrido P., García D., Carrato A., et al. New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects? Eur J Intern Med. 2019 Aug;66:1-8

Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating Rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2012;118:3977-3983.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: Clinical outcomes of the Phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–9.

Báscolo, E., Houghton, N. & Del Riego, A. Lógicas de transformación de los sistemas de salud en América Latina y resultados en acceso y cobertura de salud. Rev. Panam. Salud Pública 42, (2018).

BC Cancer Agency Cancer Drug Manual©. Asparaginase. 2013; Available at: http://www.bccancer.bc.ca/drug-database-site/Drug% 20Index/Asparaginase _monograph _1June 2013_formatted.pdf. Accessed Apr 3, 2020.

Beaven AW, Diehl LF. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. Hematology Am Soc. Hematol Educ Program. 2015;2015:550–558. doi:10.1182/asheducation-2015.1.550

Brice P., Bastion Y., Lepage E., Brousse N., Haïoun C., Moreau P., et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 Mar;15(3):1110-7

Broxmeyer H., Parker G. Impact of COVID-19 and Future Emerging Viruses on Hematopoietic Cell Transplantation and Other Cellular Therapies. Stem Cells Dev.2020 Apr 3. doi: 10.1089/scd.2020.0064. [Epub ahead of print]

Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977–987

Buege M., Kumar A., Dixon B., Tang L., Pak T., et al. Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. Ann Pharmacother. 2020 Feb 20:1060028020909117. doi: 10.1177/1060028020909117. [Epub ahead of print]

Burki T. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol 2020 Published Online April 2, 2020 https://doi.org/10.1016/ S1470-2045(20)30217-5

Carbone A, Roulland S, Gloghini A, et al. Follicular lymphoma. Nat Rev Dis Primers. 2019;5(1):83. Published 2019 Dec 12. doi:10.1038/s41572-019-0132-x.

Cederleuf H, Bjerregård Pedersen M, Jerkeman M, Relander T, d'Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. Br J Haematol. 2017;178(5):739–746. doi:10.1111/bjh.14740

Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). 2020; Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html. Accessed Apr 03, 2020.

Centers for Medicare & Medicaid Services. General Provider Telehealth and Telemedicine Tool Kit. Available at: https://www.cms.gov/files/document/general-telemedicine-toolkit.pdf. Accessed Apr 04, 2020.

Cha Z, Li C, Zang Y, et al. Adaptive B cell responses in Rituximab-treated diffuse large B cell lymphoma patients during complete remission. Tumour Biol. 2016;37(1):829–835

Chang L., Zhao L., Gong H., Wang L., Wang L. Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations. Emerg Infect Dis. 2020 Apr 3;26(7). doi: 10.3201/eid2607.200839. [Epub ahead of print]

Cheah CY, Herbert KE, O’Rourke K, Kennedy GA, George A, Fedele PL, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6):1072–9.

Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).

Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH.Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27.

Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Vol. 130, Blood. 2017. p. 867–74.

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–44.

Coronavirus (Covid-19) if you’re affected by terminal illness. Last updated: 31 March 2020. https://www.mariecurie.org.uk/help/support/coronavirus

Coronavirus disease COVID-19: EBMT Recommendations update march 30, 2020. https://www.ebmt.org/sites/default/files/2020-03/EBMT%20COVID-19%20guidelines%20v.5.1%20%282020-03-30%29.pdf

COVID-19 and Aggressive Lymphoma: Frequently Asked Questions [Internet]. 2020. Available from: https://www.hematology.org/COVID-19/COVID-19-and-aggressive-lymphoma

Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of Gemcitabine, dexamethasone, cisplatin versus dexamethasone, cytarabine, cisplatin chemotherapy before autologous stem cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG study LY.12. J Clin Oncol. 2014;32:3490–3496.

Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-1826. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23615461.

Dang X., Ogbu S., Zhao J., Nguyen L., Cao D., Nguyen L., et al. Inhibition of topoisomerase IIA (Top2α) induces telomeric DNA damage and T cell dysfunction during chronic viral infection. Cell Death Dis 2020 Mar 19;11(3):196. doi: 10.1038/s41419-020-2395-2.

Davies A., Merli F., Mihaljević B., Mercadal S., Siritanaratkul N., et al. Efficacy and safety of subcutaneous Rituximab versus intravenous Rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017 Jun;4(6):e272-e282.

Davies A., Berge C., Boehnke A., Dadabhoy A., Lugtenburg P., et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther (2017) 34:2210–2231

de Charette, M. & Houot, R. Hide or defend, the two strategies of lymphoma immune evasion: Potential implications for immunotherapy. Haematologica 103, 1256–1268 (2018).

Dong C., Ni L., Ye F., Chen M., Feng Y., et al. Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2.: https://doi.org/10.1101/2020.03.17.20036640

Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kroger N, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J. 2000;1:87–94.

Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016;387:770-778.

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1; 105(7):2677-84.

Duan K., Liu B., Li C., Zhang H., Yu T., et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 6. pii: 202004168. doi: 10.1073/pnas.2004168117. [Epub ahead of print]

Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-1925.

Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020.

Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. Hodgkin lymphoma ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2020.

Emmanuel Bach, John F. Seymour; Pierre Feugier; Fritz Offner,; Armando López-Guillermo, ; David Belada, Gilles Salles et al; Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Journal of Clinical Oncology 37, no. 31 (November 01, 2019) 2815-2824 Study DOI: 10.1200/JCO.19.01073.

Estcourt L., McQuilten Z., Powter G., Dyer C., Curnow E., et al. The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. Trials 2019 Oct 15;20(1):592

ESTRO. "Radiotherapy in a time of crisis", ESTRO Presidents' statement. Available at: https://www.estro.org/About/Newsroom/News/Radiotherapy-in-a-time-of-crisis. Accessed Apr 03, 2020.

European Centre for Disease Prevention and Control. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission

in the EU/EEA and the UK – sixth update. 2020; Available at: https://www.google.com/search?q=traductor&rlz=1C1CHBD_esCO893CO893&oq=traductor&aqs=chrome..69i57j0l7.2372j0j7&sourceid=chrome&ie=UTF-8. Accessed Apr 04, 2020.

Fan, J., Liu, X., Pan, W., Douglas, M. W. & Bao, S. Epidemiology of 2019 Novel Coronavirus Disease-19 in Gansu Province, China, 2020. Emerg. Infect. Dis. 26, (2020).

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards. https://www.fda.gov/media/136238/download

FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic. Accessed Apr 07, 2020.

FDA Statement. Coronavirus (COVID-19) Update: FDA Provides Updated Guidance to Address the Urgent Need for Blood During the Pandemic. 2020; Available at: Coronavirus (COVID-19) Update:

Ferreri AJM, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the Rituximab era. Br J Haematol. 2015 Mar;168(5):654–62.

Filippi A., Meregalli S., DI Russo A., Levis M., Ciammella P., et al. Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiat Oncol. 2020 Mar 12;15(1):62.

Flinn, I. W., van der Jagt, R., Kahl, B., Wood, P., Hawkins, T., MacDonald, D., … Burke, J. M. (2019). First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of Clinical Oncology,JCO.18.00605. doi:10.1200/JCO.18.00605. Epub 2019 Feb 27

Fossard G., Broussais F., Coelho I., Bailly S., Nicolas-Virelizier E. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018 Mar 1;29(3):715-723.

Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1: CD004386.

Ganesan P, Ganesan TS, Atreya H, et al. DA-EPOCH-R in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience. Indian J Hematol Blood Transfus. 2018;34(3):454–459. doi:10.1007/s12288-017-0901-1

Gang AO, Strøm C, Pedersen M, d'Amore F, Pedersen LM, Bukh A, Pedersen BB, Moeller MB, Mortensen LS, Gadeberg OV, Ingeberg S, Mourits-Andersen T, Pulczynski S, d Nully Brown P. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol. 2012 Jan;23(1):147-53. doi: 10.1093/annonc/mdr058. Epub 2011 Apr 2. https://www.ncbi.nlm.nih.gov/pubmed/21460380

Garcia-Robledo, J. E., Barrera, M. C. & Tobón, G. J. CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases: CRISPR/Cas9 offers a simple and inexpensive method for disease modeling, genetic screening, and potentially for disease therapy. International Reviews of Immunology 39, 11–20 (2020).

Gautret P, LagierJ-C, Parola P et. al. Hydroychloroquine and azithromycin as a treatment of COVID-19: results of an open-laberl non-randomized clinical trial. International Journal of Antimicrobial Agentes. In press. 2020. DOI: 10.1016(j.ijantimicag.2020.105949.

GELTAMO. Recomendaciones del Comité Científico del grupo GELTAMO para el manejo de los pacientes con linfoma durante la crisis del Covid-19. Available at:https://www.geltamo.com/images/PDF/Recomendaciones%20linfomas%20Covid-19%2019%20MARZO%202020.pdf. Accessed Apr 3, 2020

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem 2019 Jul;88:102925

Giudicessi J, Noseworhty PA, Friedmann P et. al. Urgent Guidance for Navigating and Circumvention of the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19. Mayo Clinic Windland Smit Rice Genetic Hearth Rhythm Clinic.

Graf S, Stevenson P, Holmberg LA, et al. Maintenance Rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26:2323-2328.

Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea, (GELTAMO). Guías de GELTAMO. Available at: https://www.geltamo.com/protocolos-2/guias-terapeiuticas. Accessed Mar 30, 2020.

Guidance for NIH-funded Clincal Trials and Human Subjects Studies Affected by COVID-19. 2020. Available at https://grants.nih.gov/grants/ guide/notice-files/NOT-OD-20-087.html. Accessed Apr 5, 2020.

Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000 Nov 1;18(21):3633-42

Hagemeister F. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002;49 Suppl 1:S13–S20. doi:10.1007/s00280-002-0447-1

Hande K., Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J cancer, 1998 Sep;34(10):1514-21.

Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, et al. NCCN Guidelines Version 1.2020 T-Cell Lymphomas. 2020 Available at:: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf Accessed Apr 1, 2020.

Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus Rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [ASH abstract 151]. Blood. 2012;120(21)(suppl).

Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol. 2006 May;17 Suppl 4:iv25-30.

Hospital Israelita Albert Einstein. Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Alliance COVID-19 Brasil II). Available at: https://clinicaltrials.gov/ct2/show/results/NCT04321278?term=azithromycin&cond=COVID-19&draw=2&rank=1&view=results. Accessed Mar 30, 2020.

Improving telemedicine helps to minimise risks for cancer patients. https://www.esmo.org/oncology-news/improving-telemedicine-helps-to-minimise-risks-for-cancer-patients

Intragumtornchai T., Sutheesophon J., Sutcharitchan P., et al. A predictive model for lifethreatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 37:351-360, 2000

Ito, K. et al. Influence of R-CHOP therapy on immune system restoration in patients with b-cell lymphoma. Oncol. 91, 302–310 (2016).

Jagannath S, Velasquez WS, Tucker SL, et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986;4(6):859–865. doi:10.1200/JCO.1986.4.6.859

Jin Y., Yang H., Ji W., Wu W., Chen S., et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. .2020 Mar 27;12(4). pii: E372. doi: 10.3390/v12040372

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–29.

Jordan, R. E., Adab, P. & Cheng, K. K. COVID-19: risk factors for severe disease and death. BMJ 368, m1198 (2020).

Kahl BS, Long WL, Eickhoff JC, et al. Maintenance Rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-1423.

Kang J., Chae H., Hong J., Yoon D., Kim S., et al. Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP. Leuk Lymphoma. 2020 Jan 6:1-7. doi: 10.1080/10428194.2019.1709831. [Epub ahead of print]

Karishma Phansalkar , Mohamed Amin Ahmed, , Nathan Fowler, Long Ma , Mansoor Noorani , Seung Tae Lee, Lei Feng, MS, Fredrick B. Hagemeister, Jorge E. Romaguera, Luis Fayad, Alma Rodriguez,, Felipe Samaniego,Michelle A. Fanale, Michael Wang, Yasuhiro Oki, Francesco Turturro, Jason R. Westin, Loretta J. Nastoupil, Larry W Kwak,, Richard E. Davis, Sattva S. Neelapu. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis Blood (2014) 124 (21): 3048. https://doi.org/10.1182/blood.V124.21.3048.3048

Klausen U., Holmberg S., Holmström M., Jørgensen N., Grauslund J., et al. Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies. Front Immunol. 2018 Oct 1;9:2264

Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020;38:248-256.

Knauf W, Abenhardt W, Mohm J, Rauh J, Harde J, Kaiser-Osterhues A, et al. Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma—data from the prospective German Tumour Registry Lymphatic Neoplasms. Eur J Haematol. 2019;103(5):460–71.

Kroschinsky F.1, Friedrichsen K., Mueller J., Pursche S., Haenel M., et al. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. Cancer Chemother Pharmacol. 2008 Apr;61(5):785-90

Kucharski A., Russell T., Diamond C., Liu Y., Edmunds J., et al. Early dynamics of transmission and control of COVID-19: A mathematical modelling study. Lancet Infect Dis. 2020 Mar 11. pii: S1473-3099(20)30144-4. doi: 10.1016/S1473-3099(20)30144-4. [Epub ahead of print]

Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med 2020. doi:10.7326/M20-1133. https://watermark.silverchair.com/aime202006160-m201133.pdf?

Kutikov, A. et al. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann. Intern. Med. (2020). doi:10.7326/M20-1133

Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, et al. Cancer care during the spread of coronavirus disease 2019 ( COVID-19 ) in Italy : young oncologists ’ perspective. Esmo Open. 2020;5(e000759).

Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 2018;131:174-181.

Lansigan F., Horwitz S.., Pinter-Brown L., Rosen S., Pro B., et al. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematol 2020;143:40–50

Laprise-Lachance M., Lemieux P., Grégoire J. Risk of pulmonary toxicity of bleomycin and filgrastim. J Oncol Pharm Pract. 2019 Oct;25(7):1638-1644. Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N, et al.

Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017;377:1250-1260..

Lee, A. Wuhan novel coronavirus (COVID-19): why global control is challenging? Public Health 179, A1–A2 (2020).

Lekakis L., Moskowitz C. The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy. Hemasphere. 2019 Dec; 3(6): e295

Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Vol. 21, The Lancet Oncology. 2020. p. 335–7.

Lyman G., Dale D., Friedberg J, et al. Incidence and predictors of low chemotherapy dose intensity in aggressive non-Hodgkin’s lymphoma: A nationwide study. J Clin Oncol 22:4302-4311, 2004

Lyman G., Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9

Mangal, N., Salem, A. H., Li, M., Menon, R., & Freise, K. J. (2017). Relationship between response rates and median progression-free survival in non-Hodgkin’s lymphoma: A meta-analysis of published clinical trials. Hematological Oncology, 36(1), 37–43. doi:10.1002/hon.2463

Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol. 2005;23(30):7614–20.

Mathias J. Rummel, Georg Maschmeyer, Arnold Ganser, Andrea Heider, Ulrich von Gruenhagen, Christoph Losem et al; Bendamustine plus Rituximab (B-R) versus CHOP plus Rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017) 7501-7501.

Maurer MJ, Ghesquières H, Link BK, et al. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol. 2018;36(16):1603–1610. doi:10.1200/JCO.2017.76.5198

Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13:1264-1274.

Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, Freedman A, Jacobson C, Fisher D, Ng S, Crombie J, Kim A, Odejide O, Davids MS, Brown JR, Jacene H, Cashen A, Bartlett NL, Mehta-Shah N, Ghobadi A, Kahl B, Joyce Armand P, Jacobsen E. Rituximab/bendamustine and Rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 Mar 10;4(5):858-867. doi: 10.1182/bloodadvances.2019001355.

Metodología de expertos consenso en medicina. Serie Monografías N°14: Escuela Andaluza de Salud Pública; 1996.

Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20-37

Ministerio de Salud y Protección Social, Colciencias, Instituto Nacional de Cancerología ESE - Guía de Práctica Clínica para la detección, tratamiento y seguimiento de leucemias linfoblástica y mieloide en población mayor de 18 años. Colombia 2017. Available at: https://www.cancer.gov.co/content/gu%C3%ADa-Linfomas-en-adultos. Accessed Apr 03, 2020.

Montoto S., López-Guillermo A., Altés A., Perea G., Ferrer A., et al. Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) in Patients With Follicular Lymphoma at First Progression. Ann Oncol. 2004;15(10):1484–1489.

Morrison V., Weller E., Habermann T., Li S., Fisher R., et al. Patterns of Growth Factor Usage and Febrile Neutropenia Among Older Patients with Diffuse Large B-Cell Non-Hodgkin Lymphoma Treated with CHOP or R-CHOP: The Intergroup Experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma. 2017 August ; 58(8): 1814–1822

Mussetti A., Maluquer C., Albasanz-Puig A., Gudiol C., Moreno G., et al. Handling the COVID-19 pandemic in the oncological setting. Lancet Haematol. 2020 Apr 1. pii: S2352-3026(20)30108-3. doi: 10.1016/S2352-3026(20)30108-3. [Epub ahead of print]

NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesR) Version 1 2020. Available at:https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed Apr 4, 2020

Ngoi N., Lim J., Ow S., Jen W., Lee M., et al. A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore. Ann Oncol. 2020 Mar 31. pii: S0923-7534(20)36410-3. doi: 10.1016/j.annonc.2020.03.306. [Epub ahead of print]

NICE (National institute for Health agnd Care excellence). COVID-19 rapid guideline: delivery of radiotherapy guideline [NG162]. 2020. Available at: https://www.nice.org.uk/guidance/NG162 Accessed Apr 03, 2020.

Nicholas, N. S., Apollonio, B. & Ramsay, A. G. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochimica et Biophysica Acta - Molecular Cell Research 1863, 471–482 (2016).

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi [Internet]. 2020;41(2):145–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32064853

O’Connor O., Lue J., Sawas A., Amengual J., Deng C., et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018 Feb;19(2):257-266

Ogimi C, Krantz EM, Golob JL, et al. Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2018;24(11):2293-2301

Overview | COVID-19 rapid guideline: delivery of systemic anticancer treatments | Guidance | NICE. [cited 2020 Apr 1]; Available from: https://www.nice.org.uk/guidance/ng161#.XoQlEhHjM-c.mendeley

Pedersen MØ, Gang AO, Brown P, Pedersen M, Knudsen H, Nielsen SL, Poulsen T, Wirenfeldt Klausen T, Høgdall E, Nørgaard P. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers. PLoS One. 2017 Oct 31;12(10):e0186983. doi: 10.1371/journal.pone.0186983. eCollection 2017. https://www.ncbi.nlm.nih.gov/pubmed/29088292

Petrich A, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 2014;124:2354-2361.

Peyrade F1, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA) investigators. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 May;12(5):460-8. doi: 10.1016/S1470-2045(11)70069-9. Epub 2011 Apr 7. https://www.ncbi.nlm.nih.gov/pubmed/21482186

Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without Rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.

Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–41.

Potenza L., Luppi M., Efficace F., Bruera E., Bandieri E. Early Palliative Care: A Necessary Intervention for Patients Ineligibile to Approved Potentially Life-saving CAR T-cell Therapy. Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):201-202

Purroy N, Bergua J, Gallur L, et al. Long-term follow-up of dose-adjusted EPOCH plus Rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol 2015;169:188-198. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25521006

Quan-xin Long, Hai-jun Deng, J et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. https://doi.org/10.1101/2020.03.18.20038018

Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. asparaginase related venous thrombosis in UKALL 2003 re-exposure to asparaginasa is feasible and safe. Br. J. Harmatol 2009;149:410-3.

Rechner L., Modiri A., Stick L., Maraldo M., Aznar M., et al. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study. Acta Oncol. 2020 Mar 27:1-9. doi: 10.1080/0284186X.2020.1733654. [Epub ahead of print]

Reinert T, Baldotto CS da R, Nunes FAP, Scheliga AA de S. Bleomycin-Induced Lung Injury. J Cancer Res. 2013;2013:1–9.

Ritchie D, Seymour J, Grigg A, et al. The hyper-CVAD–Rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007;86:101-105.

Rituxan (rituximab) . Available at: https://www.rituxan.com/hcp/dosing-and-administration/rituxan-administration/rituxan-infusion.html. Accessed Mar 03., 2020.

Rodriguez-Morales, A. J. et al. COVID-19 in Latin America: The implications of the first confirmed case in Brazil. Travel Medicine and Infectious Disease (2020). doi:10.1016/j.tmaid.2020.101613

Roschewski M, Dunleavy K, Abramson JS, et al. Risk-adapted therapy in adults with Burkitt lymphoma: Results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R [abstract]. Blood 2017;130 (Suppl 1):Abstract 188.

Rummel MJ, Knauf W, Goerner M, et al. Two years Rituximab maintenance vs. observation after first-line treatment with bendamustine plus Rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial) [abstract]. J Clin Oncol 2016;34:Abstract 7503.

Rummel, M., Niederle, N., Maschmeyer, G., Banat, G., Von Grunhagen, U., Losem, C.. (2013) Bendamustine plus Rituximab versus chop plus Rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet (London, England) 381: 1203–1210.

Saavedra CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVI 19 en establecimientos de atención de la salud. recomendaciones basadas en consenso de expertos e informadas en la evidencia. Revista Infectio 2020 Mar,;24(3). S1.

Salar A., Avivi I., Bittner B., Bouabdallah R., Brewster M., et al. Comparison of subcutaneous versus intravenous administration of Rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014 Jun 10;32(17):1782-91

Salim Mattar, V. & Marco González, T. Zoonotic emergence of coronavirus: A potential public risk for Latin America. Revista MVZ Cordoba 23, 6775–6777 (2018).

Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations. Emerg Infect Dis. 2020 Apr 3;26(7). doi: 10.3201/eid2607.200839. [Epub ahead of print]

Shander A, Goobie S, Warne M, Aapro M, Bisbe E, Perez-Calatayud A, et al. The Essential Role of Patient Blood Management in a Pandemic: A Call for Action. Anesthesia & Analgesia 2020 Mar 31,:1.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32205856.

Shree, T. et al. IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE POPULATION-BASED STUDY. Hematol. Oncol. 37, 80–81 (2019).

Shuman A:, Pentz R. Cancer Research Ethics and COVID-19. The Oncologist 2020;25:1–2

Simcock R., Thomas T., Estes C., Filippi A., Katz M., et al. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clinical and Translational Radiation Oncology 22 (2020) 55–68

Smith T., Bushek J., Prosser T. COVID-19 Drug Therapy – Potential Options. https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf

Sociedad Argentina de Hematología. Recomendaciones de la Sociedad Argentina de Hematología (SAH) . Available at: http://www.sah.org.ar/. Accessed Mar 30, 2020.

Sociedad Argentina de Hematología. Recomendaciones de la Sociedad Argentina de Hematología (SAH) . Available at: http://sah.org.ar/docs/2019/Linfomas.pdf. Accessed Mar 30, 2020.

Sociedad Española de Hematología y Hemoterápia, SEHH. Recomendaciones del Comité Científico del grupo GELTAMO para el manejo de los pacientes con Linfoma durante la crisis del COVID-19. 2020; Available at: https://www.sehh.es/COVID-19/recomendaciones/123783-recomendaciones-del-comite-cientifico-del-grupo-geltamo-para-el-manejo-de-los-pacientes-con-Linfoma-durante-la-crisis-del-COVID-19. Accessed Mar 30, 2020.

Solal-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993;329(22):1608–1614.

Sumita Ratnasingam, Joshua Casan, Jake Shortt, Eliza Hawkes, Michael Gilbertson Zoe McQuilten, George Grigoriadis, Kay Thwe Htun, Swe Myo Htet, Philip Campbel, Khai Li Chai, Hang Quach, Sushrut Patil & Stephen Opat Cytarabine-based induction immunochemotherapy in the frontline treatment of older patients with mantle cell lymphoma www.nature.com/scientificreports, 2019. 9:13544 | https://doi.org/10.1038/s41598-019-49776-9

Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. doi:10.1111/jth.14817

Taplitz R., Kennedy E., Bow E., Crews J., Gleason C., et al. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018 Oct 20;36(30):3043-3054

The European Medicines Agency, (EMA). Update on treatments and vaccines against COVID-19 under development. 2020; Available at: https://www.ema.europa.eu/en/news/update-treatments-vaccines-against-covid-19-under-development. Accessed Apr 04, 2020.

The New York Times. Flattening the Coronavirus Curve. 2020; Available at: https://www.nytimes.com/article/flatten-curve-coronavirus.html. Accessed Apr 7, 2020.

Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with Rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005;104:1434-1441.

Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, et al. Chemoimmunotherapy

with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.

Tixier F., Ranchon F., Iltis A., Vantard N., Schwiertz V., et al. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients. Hematol Oncol. 2017 Dec;35(4):584-590.

Trappe R, Oertel S, Leblond V, et al. Sequential treatment with Rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196–206

Trébucq A., Decroo T., Van Deun A., Piubello A., Chiang C., et al. Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence. J Clin Med. 2019 Dec 25;9(1)

Tse E, Kwong Y. The diagnosis and management of NK/T-cell lymphomas. Journal of hematology & oncology 2017 Apr 14,;10(1):85.

Ueda M, Martins R, Hendrie PC, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw. 2020 Mar 20:1-4. doi: 10.6004/jnccn.2020.7560. [Epub ahead of print]

Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw 2020 March 20:1-4

van 't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524-530.

Vardhana SA, Sauter CS, Matasar MJ, et al. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the Rituximab era. Br J Haematol. 2017;176(4):591–599.

Vassilakopoulos T., Asimakopoulos J., Konstantopoulos K., Angelopoulou M. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Ther Adv Hematol. 2020 Feb 16;11:2040620720902911

Vehreschild JJ, Bohme A, Cornely OA, et al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol. 2014;25(9):1709-1718

Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;71(1):117-22.

Villela L, López-Guillermo A, Montoto S, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer. 2001;91(8):1557–1562.

Voltin CA, Mettler J, Grosse J, Dietlein M, Baues C, Schmitz C, et al. FDG-PET imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated overview. Cancers (Basel). 2020;12(3):1–15.

Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716-723.

Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659-667.

Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739-745.

Wästerlid T, Hartman L, Székely E, Jerkeman M. Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol. 2017 Jun;35(2):151-157. doi: 10.1002/hon.2256. Epub 2015 Sep 15. https://www.ncbi.nlm.nih.gov/pubmed/26369736

Weinkove R., McQuilten Z., Adler J., Agar M., Blyth E., et al. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aus. 2020. [Epub ahead of print]. https://www.mja.com.au/system/files/2020-03/Preprint%20McQuilten%2020%20March%202020%20mja20.00315.pdf

Wenhua Liang, Weijie Guan, Ruchong Chen, Wei Wang, Jianfu Li, Ke Xu, Caichen Li, Qing Ai, Weixiang Lu, Hengrui Liang, Shiyue Li, Jianxing H. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020 Published Online February 14, 2020 https://doi.org/10.1016/ S1470-2045(20)30096-6 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30096-6/fulltext

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol 2020;n/a.

Wilson J., Hammond E., Higgins G., Petersson K. Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold? Front Oncol. 2020 Jan 17;9:1563

Working Group coordinated by the, EMA. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic . 2020; Available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_COVID-19_en.pdf. Accessed Apr 5, 2020.

World Health Organization. Protecting the Blood Supply During Infectious Disease Outbreaks Guidance for National Blood Services. https://www.who.int/bloodsafety/publications/protecting-blood-supply/en/; 2019.

World health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) . 2020 16-24 February:1-40.

Wu, D., Wu, T., Liu, Q. & Yang, Z. The SARS-CoV-2 outbreak: what we know. Int. J. Infect. Dis. 0, (2020).

Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J. Am. Med. Assoc. (2020). doi:10.1001/jama.2020.2648

Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients. Lancet Oncol 2020 March 03.

Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Vol. 131, Blood. 2018. 2528–2540 p.

Zaucha JM, Chauvie S, Zaucha R, Biggii A, Gallamini A. The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev [Internet]. 2019;77(May):44–56. Available from: https://doi.org/10.1016/j.ctrv.2019.06.002

Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, Peng P, Zhang P, Chu Q, Shen Q, Wang Y, Xu SY, Zhao JP, Zhou M, Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China, Annals of Oncology (2020), doi: https://doi.org/10.1016/j.annonc.2020.03.296. https://www.annalsofoncology.org/article/S0923-7534(20)36383-3/pdf

Zhang L1, Ghielmini M2, Cheson BD3, Ujjani C4.Cancer Pros and cons of Rituximab maintenance in follicular lymphoma. Treat Rev. 2017 Jul;58:34-40. doi: 10.1016/j.ctrv.2017.05.007. Epub 2017 Jun 16.

Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. 0, (2020).

Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).

Zimmer A and Freifeld A. When to use prophylactic antibiotics in neutropenic patients. Oncology 2016; 30: 838–840, 846.

Publicado
2020-05-22
Sección
Artículos especiales